Haleon Pakistan Limited

HALEON

PK0112101016

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
252 ^PKR	+1.27%		+5.60%	+49.12%

2023	Haleon Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Haleon Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

GlaxoSmithKline Consumer Healthcare Pakistan Limited Recommends Cash Dividend

March 05, 2021 at 06:14 am EST

The Board of Directors of GlaxoSmithKline Consumer Healthcare Pakistan Limited in its meeting held on March 5, 2021 recommended a cash dividend of PKR 5 per share, payable to the shareholders whose names appear in the register of the members on April 14, 2021.

Latest news about Haleon Pakistan Limited

Haleon Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-23	CI
Haleon Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Haleon Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Haleon Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-05	CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-27	CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-10-19	CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-28	CI
Unilever Looking to Reposition Portfolio After GSK Consumer Healthcare Approach -- Update	22-01-17	DJ
Unilever Looking to Reposition Portfolio Into Higher Growth Categories	22-01-17	DJ
GlaxoSmithKline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-29	CI
Glaxosmithkline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-31	CI
GlaxoSmithkline Consumer Healthcare Pakistan Limited Announces Change of Chief Executive Officer	21-04-01	CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Recommends Cash Dividend	21-03-05	CI
Glaxosmithkline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-05	CI
Appointment of Non-Executive Independent Director of Glaxosmithkline Consumer Healthcare Pakistan Limited	21-03-03	CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Announces Executive Changes	20-10-27	CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Announces Directorate Changes	20-10-27	CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Announces Directorate Changes	20-10-27	CI
Glaxosmithkline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-27	CI
Glaxosmithkline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-28	CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Announces Board Changes	20-08-26	CI
Glaxosmithkline Consumer Healthcare Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2019	20-04-29	CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Proposes Cash Dividend for the Year Ended 31 December 2019	20-04-29	CI
GlaxoSmithKline Consumer Healthcare Pakistan Limited Appoints M.Z. Moin Mohajir as Chairman of the Board of Directors	20-03-13	CI

Chart Haleon Pakistan Limited

Duration

Period

More charts

Company Profile

Haleon Pakistan Limited, formerly Glaxosmithkline Consumer Healthcare Pakistan Limited, is a Pakistan-based healthcare company. The Company's product portfolio consists of five categories, namely oral health, pain relief, respiratory health, digestive health and other, and vitamins, minerals and supplements (VMS). Its geographical segment consists of North America; Europe, Middle East & Africa (EMEA) and Latin America (LatAm), and Asia-Pacific (APAC). The Brands under Oral Health include Sensodyne, Parodontax, Polident, and Biotene. Its Vitamins, Minerals and Supplements offers a portfolio of brands, such as Centrum, a multivitamin and mineral brand; calcium supplements through its Caltrate brand, and vitamin C supplements through Emergen-C. The Brands under Respiratory consists of Otrivin, Theraflu, and Flonase. The Company's Pain Relief product includes Panadol, Voltaren and Advil brands. Its portfolio digestive health brands consists of Eno, Tums, and Fenistil.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HALEON PAKISTAN LIMITED	+49.12%	106M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+19.62%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+10.86%	14.09B
CIPLA LIMITED	+13.07%	13.64B
ZYDUS LIFESCIENCES LIMITED	+37.46%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+8.46%	5.22B